Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study-Reference-Cited by-同舟云学术

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

Published:2021-04 Issue:4 Volume:22 Page:512-524
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kuruvilla John,Ramchandren Radhakrishnan,Santoro Armando,Paszkiewicz-Kozik Ewa,Gasiorowski Robin,Johnson Nathalie A,Fogliatto Laura Maria,Goncalves Iara,de Oliveira Jose S R,Buccheri Valeria,Perini Guilherme F,Goldschmidt Neta,Kriachok Iryna,Dickinson Michael,Komarnicki Mieczyslaw,McDonald Andrew,Ozcan Muhit,Sekiguchi Naohiro,Zhu Ying,Nahar Akash,Marinello Patricia,Zinzani Pier Luigi

Funder

Merck

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial;Fermé;J Clin Oncol,2002

2. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma;Goodman;J Clin Oncol,2008

3. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant;Arai;Leuk Lymphoma,2013

4. Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma;Santoro;Blood Adv,2020

5. Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma;Puig;Haematologica,2010

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Programmed death-1 inhibitors as treatment for other subtypes of lymphomas not recommended in the guidelines: Real-world data from a single center in China;2024-02-06

2. Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review;Diagnostics;2024-02-04

3. The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis;Recent Patents on Anti-Cancer Drug Discovery;2024-02

4. Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations;Translational Oncology;2024-02

5. Immune checkpoint blockade in hematological malignancies: current state and future potential;Frontiers in Oncology;2024-01-23